ID   XMMME-001
AC   CVCL_F817
SY   IND1
DR   CLO; CLO_0009652
DR   ATCC; HB-8759
DR   Wikidata; Q54994849
RX   DOI=10.3390/antib1010039;
RX   Patent=US4590071;
RX   PubMed=6609971;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8759.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce XomaZyme-Mel (XMMME-001-RTA) which was evaluated in several clinical trials for metastatic melanoma patients (DOI=10.3390/antib1010039).
CC   Monoclonal antibody isotype: IgG2a.
CC   Monoclonal antibody target: Human melanoma tumor specific HMW antigen.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3411 ! P3X63Ag8
CA   Hybridoma
DT   Created: 11-02-13; Last updated: 21-03-23; Version: 6
//
RX   DOI=10.3390/antib1010039;
RA   Becker N., Benhar I.;
RT   "Antibody-based immunotoxins for the treatment of cancer.";
RL   Antibodies 1:39-69(2012).
//
RX   Patent=US4590071;
RA   Scannon P.J., Spitler L.E., Lee H.M., Kawahata R.T., Mischak R.P.;
RT   "Human melanoma specific immunotoxins.";
RL   Patent number US4590071, 20-May-1986.
//
RX   PubMed=6609971; DOI=10.4049/jimmunol.133.1.137;
RA   Kernan N.A., Knowles R.W., Burns M.J., Broxmeyer H.E., Lu L.,
RA   Lee H.M., Kawahata R.T., Scannon P.J., Dupont B.;
RT   "Specific inhibition of in vitro lymphocyte transformation by an
RT   anti-pan T cell (gp67) ricin A chain immunotoxin.";
RL   J. Immunol. 133:137-146(1984).
//